StartEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
0,69 $
Efter lukketid:(4,99 %)+0,035
0,73 $
Lukket: 22. nov., 17.20.18 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Seneste lukkekurs
0,72 $
Dagsinterval
0,67 $ - 0,74 $
Årsinterval
0,67 $ - 3,13 $
Markedsværdi
15,20 mio. USD
Gns. volumen
90,14 t
P/E-værdi
-
Udbytteprocent
-
Primær børs
NASDAQ
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | sep. 2024info | År til år-ændring |
---|---|---|
Indtægt | 4,13 mio. | -10,38 % |
Driftsudgifter | 4,85 mio. | -10,01 % |
Nettoindtægt | -2,07 mio. | 38,42 % |
Overskudsgrad | -50,18 | 31,30 % |
Earnings per share | — | — |
EBITDA | -2,23 mio. | 10,97 % |
Effektiv afgiftssats | — | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | sep. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 8,29 mio. | -16,55 % |
Samlede aktiver | 29,21 mio. | -6,33 % |
Samlede passiver | 14,34 mio. | -9,96 % |
Samlet egenkapital | 14,87 mio. | — |
Shares outstanding | 22,00 mio. | — |
Kurs/indre værdi | 1,06 | — |
Afkast af aktiver | -23,48 % | — |
Afkast af kapital | -33,02 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | sep. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | -2,07 mio. | 38,42 % |
Pengestrøm fra drift | -2,28 mio. | 32,09 % |
Pengestrøm fra investering | -8,00 t | 52,94 % |
Pengestrøm fra finansiering | 4,69 mio. | — |
Nettoændring i likviditet | 2,41 mio. | 171,42 % |
Fri pengestrøm | -1,11 mio. | 57,80 % |
Om
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
Administrerende direktør
Grundlagt
2005
Hovedkvarter
Website
Ansatte
70